Guojian Yin

Dr. Guojian Yin


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
WXWenqin Xiao
Wenqin Xiao
GYGuojian Yin
Guojian Yin
YFYu Ting Fan
Yu Ting Fan
LQLei Qiu
Lei Qiu
XCXiao Feng Cang
Xiao Feng Cang
RWRong Wan
Rong Wan
Catalpol, an iridoid glucoside extracted from the traditional Chinese herbal medicine, Rehmannia glutinosa, is reported to exert neuroprotective, anti-inflammatory, anti-tumor and anti-apoptotic effects. The main aim of the present study was to investigate whether catalpol ameliorates experimental acute pancreatitis (AP) induced by sodium taurocholate (STC). AP was induced in rats via retrograde injection of 4% STC (0.1 mL/100 g) into the biliopancreatic duct. Rats were pre-treated with saline or catalpol (50 mg/kg) 2 h before STC injection. At 12, 24 and 48 h after injection, the severity of AP was evaluated using biochemical and morphological analyses. Pretreatment with catalpol led to a significant reduction in serum amylase and lipase activities, pancreatic histological damage, myeloperoxidase (MPO) activity, interleukin (IL)-1β, IL-6 and TNF-α levels, and activation of nuclear factor kappa B (NF-κB). Moreover, administration of catalpol increased the viability of pancreatic acinar cells and inhibited NF-κB expression in vitro. Our results collectively support the potential of catalpol as a highly effective therapeutic agent for treatment of AP.

1 October 2016 in Pancreas
Verified
Journal Article
Closed access
GYGuojian Yin
Guojian Yin
GHGuoyong Hu
Guoyong Hu
RWRong Wan
Rong Wan
GYGe Yu
Ge Yu
XCXiaofeng Cang
Xiaofeng Cang
XWXingpeng Wang
Xingpeng Wang
Objectives Mesenchymal stem cells (MSCs) have shown an obvious protective effect on acute pancreatitis (AP). The purpose of the present study was to analyze the effect of bone marrow MSC-derived microvesicles (bmMSC-MVs) on AP and explore the underlying mechanisms. Methods Bone marrow MSCs and bmMSC-MVs were isolated from Sprague-Dawley rats. Cerulein-induced mild AP (MAP) and sodium taurocholate-induced severe AP (SAP) were used as AP models in vivo and in vitro. Pancreatic injury was evaluated by measuring serum levels of amylase, lipase, chemokines, and interleukins, and by pancreatic histology, reverse transcription-polymerase chain reaction, Western blotting, and immunohistochemistry. The effects of bmMSC-MVs on the survival rates of pancreatic acinar cells in vitro were also assessed. Results Bone marrow MSC-MVs attenuated acute pancreatic injury in MAP and SAP by regulating IL-1α, IL-6, and TNF-α, and dramatically attenuated the nuclear translocation of NF-κB p65 in MAP and SAP. Bone marrow MSC-MVs improved the survival rates of pancreatic acinar cells in MAP and SAP models in vitro. Conclusions Bone marrow MSC-MVs played a protective role in AP by reducing the levels of proinflammatory cytokines and regulating the nuclear translocation of NF-κB p65. Bone marrow MSC-MVs could be developed as a strategy for the clinical treatment of SAP.

1 May 2018 in Pancreas
Verified
Journal Article
Closed access
QYQiang Yu
Qiang Yu
JZJianhong Zhu
Jianhong Zhu
XSXiaolei Sheng
Xiaolei Sheng
LXLimin Xu
Limin Xu
KHKewei Hu
Kewei Hu
GYGuojian Yin
Guojian Yin
Objectives: The purpose of this study is to assess the effect and possible mechanism of luteolin on chronic pancreatitis (CP).Methods: Trinitrobenzenesulfonic acid–induced CP was used as CP models in vivo. After the intervention of luteolin for 28 days, chronic pancreatic injury was assessed by serum hydroxyproline and pancreatic histology. α-Smooth muscle actin (α-SMA) expression was performed to detect the activation of pancreatic stellate cells (PSCs). Pancreatic stellate cells were also isolated and cultured in vitro, and the effect of luteolin on PSCs was evaluated. Transforming growth factor β (TGF-β1) signaling and its regulated mRNA expression was tested by Western blot and quantitative real-time polymerase chain reaction, respectively.Results: The protective role of luteolin on CP was confirmed by increased pancreas/body weight ratio, decreased pancreas hydroxyproline level, and reduced fibrosis. α-SMA expressions in PSCs were significantly decreased both in vitro and in vivo after the management of luteolin. Pancreas TGF-β1 expression was significantly decreased by luteolin. Luteolin inhibited the proliferation and activation of PSCs in a dose-dependent manner.Conclusions: Luteolin played a protective role in CP in many aspects, partly by regulating release of inflammatory cytokines through TGF-β1 signaling pathway.

8 February 2024 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
YLYuxin Liu
Yuxin Liu
SDSi Dai
Si Dai
SQShuqi Qin
Shuqi Qin
JZJing Zhou
Jing Zhou
ZWZhendan Wang
Zhendan Wang
GYGuojian Yin
Guojian Yin
Background and aims: To study the role of gene mutations in the development of severe hypertriglyceridemia (HTG) in patients with hyperlipidemic acute pancreatitis (HLAP), especially different apolipoprotein A5 (APOA5) mutations.Methods: Whole-exome sequencing was performed on 163 patients with HLAP and 30 patients with biliary acute pancreatitis (BAP). The pathogenicity of mutations was then assessed by combining clinical information, predictions of bioinformatics programs, information from multiple gene databases, and residue location and conservation. The pathogenic mutations ofAPOA5were visualized using the software.Results: 1. Compared with BAP patients, pathogenic mutations ofAPOA5were frequent in HLAP patients; among them, the heterozygous mutation of p.G185C was the most common.2. All six pathogenic mutations ofAPOA5identified in this study (p.S35N, p.D167V, p.G185C, p.K188I, p.R223C, and p.H182fs) were positively correlated with severe HTG; they were all in the important domains of apolipoprotein A-V (apoA-V). Residue 223 is strictly conserved in multiple mammals and is located in the lipoprotein lipase (LPL)-binding domain (Pro215–Phe261). When Arg 223 is mutated to Cys 223, the positive charge of this residue is reduced, which is potentially destructive to the binding function of apoA-V to LPL.3. Four newAPOA5mutations were identified, namely c.563A > T, c.667C > T, c.788G > A, and c.544_545 insGGTGC.Conclusions: The pathogenic mutations ofAPOA5were specific to the patients with HLAP and severe HTG in China, and identifying such mutations had clinical significance in elucidating the etiology and subsequent treatment.Graphical

13 October 2023 in Pancreatology
Verified
Journal Article
Closed access
WPWan Pu
Wan Pu
WTWen Tang
Wen Tang
YSYaoliang Shen
Yaoliang Shen
FJFengjie Ji
Fengjie Ji
JHJiujing Huang
Jiujing Huang
GYGuojian Yin
Guojian Yin

21 January 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YLYuxin Liu
Yuxin Liu
SQShuqi Qin
Shuqi Qin
SDSi Dai
Si Dai
JZJing Zhou
Jing Zhou
ZWZhendan Wang
Zhendan Wang
GYGuojian Yin
Guojian Yin
Preventing moderately severe and severe acute pancreatitis (MSAP & SAP) is the primary goal of the management of hyperlipidemic acute pancreatitis (HLAP). The main aim of this study was to investigate the factors affecting serum triglyceride (TG) clearance, particularly blood glucose (GLU) levels, which could potentially help to prevent the development of MSAP & SAP. The clinical data from 177 patients with MSAP & SAP and 195 patients with mild acute pancreatitis (MAP) on days 1–6 after the onset were collected and analyzed by multivariate logistic regression to identify the factors that have an impact on the severity of HLAP, especially TG. The optimal TG threshold was obtained by receiver operating characteristic (ROC) analysis to differentiate TG fast-clearance patients from TG slow-clearance patients, as defined in this study. Metabolism-related factors that may interfere with TG clearance, such as GLU, diabetes mellitus (DM), obesity, and uric acid, were further analyzed. Day 2 TG was an independent risk factor for MSAP & SAP in patients with HLAP (OR: 3.718, 95% CI: 2.042–6.77; P < 0.001). And patients with TG slow-clearance (day 2 TG ≥ 7.335 mmol/L) were more likely to develop MSAP & SAP (sensitivity 0.932, specificity 0.898), severe pancreatic necrosis, and death. DM (OR: 3.574, 95% CI: 1.13–11.308, P < 0.001) and day 2 GLU (OR: 1.537, 95% CI: 1.292–1.675; P < 0.001) were independent risk factors for TG slow-clearance but not for HLAP severity (OR: 1.728, P = 0.253 and OR: 1.119, P = 0.059). Day 2 GLU decreased below 13.07 mmol/L and 6.575 mmol/L in patients with DM and non-diabetes mellitus (NDM), respectively, contributing to the reduction of day 2 TG to 7.335 mmol/L. Day 2 TG levels had the most impact on the severity of HLAP, which also accurately predicted the occurrence of MSAP & SAP. It is worth noting whether the GLU can reach the target value on day 2, as it can directly affect the TG clearance rate and indirectly affect the severity of HLAP.